Sareum Share Discussion Threads

[gekko2023] 10/7/2022 11:23

Sunday Telegraph articleToday 11:01

See page 8
"Oxford's towering biotech dream has come crashing down to earth"
OK it relates to just one company but comments like ""Aim is on its knees as a market for biotech" makes one think a little.
However I would hope that as our products are pretty far down the road we will not be affected.
Any thoughts Fellow Sareumers??!

From LSE today...chickens coming home to roost...xxx

[gekko2023] 10/7/2022 08:47

Excited for this share.. house broker suggests upside of 60%...we are gonna be rich...xx

[criticalthinker1] 09/7/2022 23:26

Reference to Potential SRA737 Opportunity in Sierra Oncology Investor Call

Cambridge, UK, 6 August 2021 – Sareum Holdings plc (AIM: SAR), the specialist drug development company, notes that Sierra Oncology, the licence holder for SRA737 (a novel Chk1 inhibitor), held an investor call last night at 10pm BST to discuss its newly announced global in-licensing agreement with AstraZeneca for AZD5153, a novel BRD4 BET inhibitor, to expand its myelofibrosis pipeline.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed to Sierra in September 2016.

In discussing the rationale for adding AZD5153 to its pipeline, Sierra referred to possible pipeline expansion opportunities in other haematologic or solid tumour indications, through potential combinations with SRA737, immune-oncology agents, PARP inhibitors and drugs with other mechanisms of action.

Sierra also noted that AZD5153 had shown preclinical efficacy in combination with a diverse range of agents, and that synergy between AZD5153 and a family of DNA damage response agents, known as ATR inhibitors, suggested potential utility in combination with SRA737.

In its 10-K filing, published yesterday, Sierra reiterated that it is focusing its resources on the development of momelotinib and exploring options to potentially support the continued development of SRA737.

Sareum’s CEO, Dr Tim Mitchell, commented:

“It is encouraging to note from Sierra’s investor call that, while it has made no commitment towards the further development of SRA737, it sees further potential opportunities for this novel agent following the addition of AZD5153 into its pipeline. We remain optimistic that Sierra will find a solution to advance development of the SRA737 programme in the future.”

It is definitely not all about momo!!!!

Consolidation. Price drop. Definitely buys post Consolidation but kept steady..that will be PH spending our money for what I saw as huge buys but ended with minor sells to settle the price. This is being manipulated and the BOD know it.
Sri Lanka.

[criticalthinker1] 09/7/2022 23:16

With regards to the Chk1 inhibitor SRA737, the licensee, Sierra Oncology Inc. (“Sierra”;), noted in August 2020 that it was exploring options to support the continued development of SRA737. This candidate has demonstrated encouraging preliminary results in Phase 1/2 clinical trials, particularly in anogenital cancer, and promising data from preclinical studies in combination with a range of other therapeutic approaches. The Board was pleased to see that both clinical trials are now being reported as completed on the website www.clinicaltrials.gov and looks forward to the final results being disclosed. The Company remains in dialogue with CRT Pioneer Fund (CPF), the licensor of SRA737 to Sierra, and will update the market with any meaningful developments.
OK got that

[criticalthinker1] 09/7/2022 21:04

EU CLINICAL REGISTER

EudraCT Number: 2015-004467-36 Sponsor Protocol Number: SRA737-02 Start Date*: 2016-04-13
Sponsor Name:Sierra Oncology, Inc.
Full Title: A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Gemcitabine plus Cisplatin or Gemcitabine Alone in Subjects with Advanced Cancer
Medical condition: Histologically or cytologically proven solid tumours where treatment with gemcitabine plus cisplatin or gemcitabine alone is considered appropriate by the Investigator.
Disease: Version SOC Term Classification Code Term Level
20.0 100000004864 10049280 Solid tumour LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: GB (Completed) ES (Prematurely Ended)
Trial results: View results

Just go to the link and check out dates and tests.

It was never just about momo.

[gekko2023] 09/7/2022 18:47

You seem very distressed...is the falling share price making you cry... xxx

[gekko2023] 09/7/2022 16:12

I think that Faileum, with immediate effect, needs to put itself up for sale. For too long, this nonsense has all been jam tomorrow. If what we have is so great , then it seems obvious that interest in buying us would then follow. Time to test the theory...who exactly supposedly want sareum?! Time to find out...xxx

[norma_stitts] 09/7/2022 15:25

Gekko20238 Jul '22 - 19:05 - 11260 of 11262 (Filtered)

0 0 0
Gekko20238 Jul '22 - 19:58 - 11261 of 11262 (Filtered)

0 0 0
Gekko20239 Jul '22 - 12:42 - 11262 of 11262 (Filtered)


😂 Talking to itself I assume? What a raspberry ripple.

[gekko2023] 09/7/2022 12:42

Be afraid, very afraid, of where the share price is going to go next. No news...no deals...no updates..complete disinterest in what is happening with 737...amateurish BOD...even Thoth2 has sold out his shares...only way is down.. xx

[gekko2023] 08/7/2022 19:05

OK, so the share price closed about 2% higher...but down c.11% for the week.
Great to see PH value us at £3 a share! Froth2 would be annoyed...if he hadn't cashed out already!

[kris akabusi] 08/7/2022 16:22

Buying opportunity, finest fruit conserve tomorrow

[gekko2023] 08/7/2022 13:44

Question to all the sensitive LTHs on here who have made squillions: if you were trying to promote an investment in this company to a new investor...how would you sell it?! Because all I now see is a falling share price and jam tomorrow! xxx

[horridhenry] 08/7/2022 13:31

the fool is in are pokits